Ayoka Systems Tech Brief: Artificial Intelligence Unlocks New Data to Treat Mental Health

Industry: Software

To accelerate research in mental health conditions, such as depression, bipolar, schizophrenia or cognitive disorders like dementia or Alzheimer's disease, Ayoka has developed a patent-pending Artificial Intelligence (AI) platform.

Dallas, TX (PRUnderground) December 4th, 2019

To accelerate research in mental health conditions, such as depression, bipolar, schizophrenia or cognitive disorders like dementia or Alzheimer’s disease, Ayoka has developed a patent-pending Artificial Intelligence (AI) platform. Today, therapies and drug treatments for cognitive and neurological health disorders are manually evaluated by highly skilled and trained scientists who personally watch behavioral analysis videos, then try to consistently log and score behavior changes.

This AI-powered behavioral analysis application is a cloud-based, software-as-a-service platform that accelerates research by automating the analysis of video recordings to measure time, displacement and interaction that organisms have with objects.

This cloud-based SaaS application applies deep learning, a type of Artificial Intelligence (AI) machine learning that enables software to automatically learn and improve from experience.  With AI, the software is highly flexible, capable of teaching itself to recognize a wide variety of organisms and behaviors.  Further, the software automatically generates data not possible for humans to produce while observing behavioral assessment videos, such as tracking and calculating the distance between the center of mass of an object or center of mass for a designated part of an organism.

Automation accelerates the overall research process, by allowing scientists to record multiple test group videos, each with a distinct genetic change or variation in drug therapy, then simply upload videos to the cloud for automated generation of reports on behavioral changes and heatmaps of activity. Rather than limit the pace of research to split testing (A/B testing) for one control group and one modified group of mice over a two year span, users can perform automated, multivariate testing on genetic factors or drug therapies to treat disorders that manifest as behavioral changes, such as cognitive impairments, eating, sleep, or mental health disorders.

About Ayoka Systems

Print Friendly, PDF & Email

Become a Fan

Press Contact

Name
Eknauth Persaud
Phone
(817) 210-4042
Email
info
ce5c331f72fed181ff9603f9e633f328
@ayokasystems.com
Website